• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

The treatment of benign lesions of the proximal femur with nonvascularised autologous fibular strut grafts

    Dr. Shailesh Kumar, Dr. Sanjeev Kumar Rakesh, Dr. Gangdayal Sharma, Dr. Kumar Nitesh

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 5848-5854

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Introduction: The relative use of the non-vascularised fibula grafts was recommended
as the gold standard for the biological reconstructions has been in practice for more
than 60 years. The aim and objective of this retrospective study was primarily focussed
to analyse the results with regard to variables such as consolidation, hypertrophy at the
graft-host junctions and presence of certain complications as well as to assess the
functional and oncological outcomes.
Materials and Methodology: Fifteen patients reported with primary benign tumours
involving the proximal femur includes the femoral neck were treated surgically at the
department of orthopaedics, IGIMS Patna between October 2019 and March 2021.
There were ten males and five females. Their average age at the time of presentation
was 34 years (21–68) and the average follow-up time was considered up to 12 months.
Results: Intraoperative blood transfusion was required in eight patients (53%;
autologous blood transfusion in five, blood component transfusion in three).There was
no significant difference in the duration of restriction of full weight-bearing between the
patients who were treated with CPC and CHA (p = 0.52, Mann-Whitney U test). All
patients had equally regained full physical function without the development of pain in
the final follow-up period.
Conclusion: To conclude, it has been suggested that the management of the bone lesions
involving the proximal femur with the use of compression hip screw and synthetic bone
graft is considered as relatively safe and effective method.
Keywords:
    benign tumour proximal femur non-vascularised grafts Autologous
  • PDF (173 K)
  • XML
(2022). The treatment of benign lesions of the proximal femur with nonvascularised autologous fibular strut grafts. European Journal of Molecular & Clinical Medicine, 9(3), 5848-5854.
Dr. Shailesh Kumar, Dr. Sanjeev Kumar Rakesh, Dr. Gangdayal Sharma, Dr. Kumar Nitesh. "The treatment of benign lesions of the proximal femur with nonvascularised autologous fibular strut grafts". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 5848-5854.
(2022). 'The treatment of benign lesions of the proximal femur with nonvascularised autologous fibular strut grafts', European Journal of Molecular & Clinical Medicine, 9(3), pp. 5848-5854.
The treatment of benign lesions of the proximal femur with nonvascularised autologous fibular strut grafts. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 5848-5854.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 57
  • PDF Download: 108
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus